Urology
Volume 73, Issue 2 , Page 362 , February 2009

Reply

  • David J. Sher, M.D., M.P.H.

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • William K. Oh, M.D.

      Affiliations

    • Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

References 

  1. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–1126
  2. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52–58
  3. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol. 2000;163:824–827
  4. Sher DJ, Mantzoros C, Jacobus S, et al. Absence of a relationship between steroid hormone levels and prostate cancer grade. Urology. 2009;73:356–361
  5. Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European prospective investigation into Cancer and nutrition. Int J Cancer. 2007;121:1331–1338
  6. Fodstad P, Bjoro T, Torlakovic G, Fossa SD. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol. 2002;168:1188–1192
  7. Heracek J, Hampl R, Hill M, et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids. 2007;72:375–380
  8. Nishiyama T, Ikarashi T, Hashimoto Y, et al. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol. 2006;176:1387–1391

PII: S0090-4295(08)01563-X

doi: 10.1016/j.urology.2008.09.016

Urology
Volume 73, Issue 2 , Page 362 , February 2009

Article Tools